Pipeline

About Brequinar

As a host-targeting, oral antiviral drug candidate, brequinar blocks de novo pyrimidine biosynthesis, a pathway involved in DNA and RNA metabolism. In vitro and in vivo studies have shown that brequinar has potent antiviral activity against a wide range of viruses, including SARS-CoV-2.

 

Because brequinar acts on the host cell, it has the potential to deliver broad-spectrum antiviral activity either as a standalone therapy or in combination with direct-acting antiviral drugs, such as nucleoside analogs.

Clear Creek Bio is focused on rapidly developing brequinar as an antiviral for COVID-19 and other viruses with pandemic potential.

585 Massachusetts Avenue
Cambridge, MA 02139
info@clearcreekbio.com

© Clear Creek Bio, 2021  |  Privacy Policy  |  Terms  |  Design by Ape to Zebra